{"doi":"10.1002/mds.29271","title":"Reduced <scp>D<sub>2</sub></scp>/<scp>D<sub>3</sub></scp> Receptor Binding and Glucose Metabolism in a Macaque Model of Huntington's Disease","abstract":"Abstract Background Dopamine system dysfunction and altered glucose metabolism are implicated in Huntington's disease (HD), a neurological disease caused by mutant huntingtin (mHTT) expression. Objective The aim was to characterize alterations in cerebral dopamine D 2 /D 3 receptor density and glucose utilization in a newly developed AAV‐mediated NHP model of HD that expresses mHTT throughout numerous brain regions. Methods Positron emission tomography (PET) imaging was performed using [ 18 F]fallypride to quantify D 2 /D 3 receptor density and 2‐[ 18 F]fluoro‐2‐deoxy‐ d ‐glucose ([ 18 F]FDG) to measure cerebral glucose utilization in these HD macaques. Results Compared to controls, HD macaques showed significantly reduced dopamine D 2 /D 3 receptor densities in basal ganglia ( P &lt; 0.05). In addition, HD macaques displayed significant glucose hypometabolism throughout the cortico‐basal ganglia network ( P &lt; 0.05). Conclusions [ 18 F]Fallypride and [ 18 F]FDG are PET imaging biomarkers of mHTT‐mediated disease progression that can be used as noninvasive outcome measures in future therapeutic studies with this AAV‐mediated HD macaque model. © 2022 International Parkinson and Movement Disorder Society.","journal":"Movement Disorders","year":2022,"id":281862,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9562,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":957509,"name":"Daniele Bertoglio","orcid":"0000-0003-4205-5432","position":1,"is_corresponding":false},{"id":301292,"name":"William A. Liguore","orcid":"0000-0002-6853-1882","position":2,"is_corresponding":false},{"id":894731,"name":"Kristin Brandon","orcid":null,"position":3,"is_corresponding":false},{"id":957994,"name":"John Templon","orcid":null,"position":4,"is_corresponding":false},{"id":924862,"name":"Jeanne Link","orcid":"0000-0002-9063-0203","position":5,"is_corresponding":false},{"id":301295,"name":"Jodi L. McBride","orcid":"0000-0002-4816-7569","position":6,"is_corresponding":false},{"id":301291,"name":"Alison R. Weiss","orcid":"0000-0002-1821-8193","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-19T00:29:15.734856Z","pmid":"36544385","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}